Skip to main content
SpringerLink
Log in

Stellenwert der Lebensqualität beim Ovarialkarzinom: Eine aktuelle Bestandsaufnahme

  • Chapter
Management des Ovarialkarzinoms

Part of the book series: Onkologie aktuell ((ONKAKTUELL))

  • 1323 Accesses

Auszug

Trotz deutlich verbesserter Operationstechniken und hoher Ansprechraten von ca. 75% der First-Line-Chemotherapie mit Paclitaxel und Carboplatin entwickeln etwa 65% der Patientinnen mit FIGO-Stadium III und IV ein Rezidiv oder eine Tumorprogression und versterben an dieser Erkrankung (Sehouli et al. 2003). Der Großteil der Patientinnen weist ein primäres Tumorstadium III oder IV auf. Der Lebensqualität kommt somit beim Ovarialkarzinom eine besondere Rolle zu.

für die Arbeitsgruppe „Quality of Life“ der Nord=Ostdeutschen Gesellschaft für Gynäkologische Onkologie (NOGGO)

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 44.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Anderson B: Quality of life in progressive ovarian cancer. Gynecologic Oncology, 1994, 55: S151–S155

    PubMed  CAS  Google Scholar 

  • Cassidy J, Paul J, Soukop M, Habeshaw T, Reed NS, Parkin D, Kaye SB. Clinical trials of nim odipine as a potential neuroprotector in ovarian cancer patients treated with cisplatin. Cancer Chemother Pharmacol 1997, 41: 161–166.

    Article  Google Scholar 

  • Cella DF, Tulsky DS, Gray G et al. The Functional Assessment of Cancer Therapy scale: Development and validation of the general measure. J Clin Oncol, 1993, 11: 570–579

    PubMed  CAS  Google Scholar 

  • Chang VT, Thaler HT, Polyak TA, Kornblith AB, Lepore JM, Portenoy RK. Quality of life and survival: the role of multidimensional symptom assessment. Cancer 1998, 83 (1): 173–179

    Article  PubMed  CAS  Google Scholar 

  • Coates A, Gebski V. On the receiving end VI. Which dimensions of quality of life scores carry prognostic information? Ca Treat Rev 1996, 22 (Suppl A): 63–67

    Article  Google Scholar 

  • Coates A, Fischer Dillenbeck C et al. On the receiving end II. Linear Analogue Self-Assessment (LASA) in evaluation of aspects of the quality of life of cancer patients receiving therapy. European Journal Cancer Clinical Oncology, 1983, 11: 1633–1637

    Article  Google Scholar 

  • Cull A, Howat S, Greimel E, Waldenstrom AC et al. Development of a European Organization for Research and Treatment of Cancer questionnaire module to assess the quality of life of ovarian cancer patients in clinical trials: a progress report. Eur J Cancer 2001, 37: 47–53

    Article  PubMed  CAS  Google Scholar 

  • Dancey J, Zee B, Osoba D, Whitehead M, Lu F, Kaizer L, Latreille J, Pater JL. Quality of life scores: an independent prognostic variable in a general population of cancer patients receiving chemotherapy. The National Cancer Institute of Canada Clinical Trials Group. Qual Life Res 1997, 6 (2):151–158

    Article  PubMed  CAS  Google Scholar 

  • Ersek M, Ferrell BR, Dow KH, Melancon CH. Quality of life in women with ovarian cancer. Western Journal of Nursing Research, 1997, 19 (3):334–350

    Article  PubMed  CAS  Google Scholar 

  • Fish LS, Lewis BE. Quality of life issues in the management of ovarian cancer. Seminars in Oncology, 1999, Vol 26 No. 1, Supplement I (February): 32–39

    PubMed  CAS  Google Scholar 

  • Ganz PA: Quality of life and the patient with cancer: individual and policy implications. Cancer 1994, 74: 1445–1452

    Article  PubMed  CAS  Google Scholar 

  • Ganz PA, Lee J, Siau J. Quality of life assessment. An independent prognostic variable for survival in lung cancer. Cancer, 1991, 67: 3131–3135

    Article  PubMed  CAS  Google Scholar 

  • Greimel E, Bjelic-Radisic, Pfisterer J, Hilpert F, Bois A du. Randomized study of the Arbeitsgemeisnchaft Gynaekologische Onkologie Ovarian cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel. J Clin Oncol 2006, 24: 579–586

    Article  PubMed  CAS  Google Scholar 

  • Haes JC de, Knippenberg FC van, Neijt JP. Measuring psychological and physical distress in cancer patients: structure and applications on the Rotterdam Symptom Check List. Br J Cancer 1990, 62: 1234–1238

    Google Scholar 

  • Hays RD, Anderson R, Revicki D. Psychometric considerations in evaluating health-related quality of life measures. Quality of Life Research 1993, 2: 441–449

    Article  PubMed  CAS  Google Scholar 

  • Herndon JE, Fleishman S, Kornblith AB, Kosty M, Green MR, Holland J. Is quality of life predictive of the survival of patients with advanced nonsmall cell lung carcinoma? Cancer, 1999, 85 (2): 333–340

    Article  PubMed  Google Scholar 

  • Hunt SM, McEwen J, McKenna SP, Williams J, Papp E. The Nottingham Health Profile: subjective health status and medical consultations. Soc Sci Med, 1981, 15 A: 221–229

    Google Scholar 

  • Katsares, I, Sehouli J, Stengel D et al. Can the assessment of quality of life (QOL) be used as an additional instrument, to evaluate clinical response on palliative treatment in patients with gynecological malignancies? Results of a prospective study. Journal of Cancer Research and Clinical Oncology, 2004, 130, PO826: 180

    Google Scholar 

  • King CR, Haberman M, Berry DL et al. Quality of life and the cancer experience: The state-of-the-knowledge. Oncol Nurs Forum 1997, 24: 27–41

    PubMed  CAS  Google Scholar 

  • Könsgen D, Sehouli J, Katsares I, Oskay G, Stengel D, Porzsolt F, Lichtenegger W on behalf of the Evidence-Based Medicine study group of the NOGGO e.V. Is quality of life a prognostic factor in ovarian cancer? 38th ASCO Annual Meeting, 2002, Abstract 2814

    Google Scholar 

  • Montazeri Ali, McEwen James, Gillis Charles R. Quality of life in patients with ovarian cancer: Current state of research. Support Care Cancer, 1996, 4: 169–179

    Article  PubMed  CAS  Google Scholar 

  • Osoba D, Zee B, Prater J, Warr D, Kaizer L, Latreille J. Psychometric properties and responsiveness of the EORTC Quality of Life Questionnaire (QLQ-30) in patients with breast, ovarian and lung cancer. Quality of Life Research, 1994, 3: 353–364

    Article  PubMed  CAS  Google Scholar 

  • Parsons SL, Murawa PX, Kolesnik OO. Treatment of epithelial cancer patients with malignant ascites using catum axomab: Results of the non-ovarian stratum of a phase II/III study. J Clin Oncol 2008; 26 (20S): ASCO 2008: # 106

    Google Scholar 

  • Patnaik A, Doyle C, Oza AM. Economic evaluation of chemotherapy: Palliative therapy in advanced ovarian cancer: balancing patient expectations, quality of life and cost. Anti-Cancer Drugs, 1998, 9 (10)

    Google Scholar 

  • Penson et al. Attitudes to chemotherapy to chemotherapy in patients with ovarian cancer, ASCO, 2003, Abstract 1888

    Google Scholar 

  • Pfisterer J, Plante M, Vergote I et al. Ergebnisse einer randomisierten Phase-III-Studie der »Gynecologic Cancer Intergroup« (GCIG) der AGO OVAR, NCIC CTG und EORTC GCG. Proceedings of ASCO, 2004, Abstract 5005

    Google Scholar 

  • Portenoy RK, Thaler HT, Kornbilth AB et al. The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, charactertics and distress. European Journal of Cancer, 1994, 30A (9): 1326–1336

    Article  PubMed  CAS  Google Scholar 

  • Porzsolt, F. Ist die Messung der Lebensqualität möglich und notwendig? Warum Sie die Lebensqualität Ihrer Patienten messen sollten. Der Allgemeinarzt 1996; 18 (6): 610–624

    Google Scholar 

  • Ringdal GI, Götestam KG, Kaasa S, Kvinnsland S, Ringdal K. Prognostic factors and survival in a heterogeneous sample of cancer patients. Br J Cancer 1996, 73 (12): 1594–1599

    PubMed  CAS  Google Scholar 

  • Sehouli J, Lichtenegger W (Hrsg). Multimodales Management des Ovarialkarzinoms Unimed, Bremen 2006.

    Google Scholar 

  • Sehouli J, Könsgen D, Klapp C et al. Lebensqualität in der gynäkologischen Onkologie. Geburtsh Frauenheilk 2003, 63: 752–757

    Article  Google Scholar 

  • Vasey PA on behalf of the Scottish Gynaecological Cancer Trials Group, CRS Trials Unit Glasgow, UK. Survival and longer-tem toxicity results of the SCOTROC study: docetaxel-carboplatin (DC) vs. paclitaxel-carboplatin (PC) in epithelial ovarian cancer (EOC) 38th ASCO Annual Meeting, 2002, Abstract 804

    Google Scholar 

  • Walle U, Sehouli J, Stengel D et al. on behalf of the NOGGO Study Group.Development of a symptom-check-list for patients with advanced ovarian cancer, results from a phase I and II clinical trial. 37th ASCO Annual Meeting, 2001, Abstract 2531

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Frauenheilkunde und Geburtshilfe Charité Campus Virchow-Klinikum, Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin

    Prof. Dr. J. Sehouli, Dr. med. D. G. Oskay-Özcelik, Dr. med. R. Chekerov & Prof. Dr. med. W. Lichtenegger

Authors
  1. Prof. Dr. J. Sehouli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dr. med. D. G. Oskay-Özcelik
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dr. med. R. Chekerov
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Prof. Dr. med. W. Lichtenegger
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer Medizin Verlag Heidelberg

About this chapter

Cite this chapter

Sehouli, J., Oskay-Özcelik, D.G., Chekerov, R., Lichtenegger, W. (2009). Stellenwert der Lebensqualität beim Ovarialkarzinom: Eine aktuelle Bestandsaufnahme. In: Management des Ovarialkarzinoms. Onkologie aktuell. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-68857-0_19

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-68857-0_19

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-41987-7

  • Online ISBN: 978-3-540-68857-0

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation